E Fund Management Co. Ltd. Has $1.20 Million Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

E Fund Management Co. Ltd. increased its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 75.1% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 4,926 shares of the biopharmaceutical company’s stock after buying an additional 2,112 shares during the quarter. E Fund Management Co. Ltd.’s holdings in Alnylam Pharmaceuticals were worth $1,197,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently made changes to their positions in the company. Norges Bank acquired a new stake in Alnylam Pharmaceuticals during the 4th quarter valued at approximately $390,438,000. Capital International Investors increased its position in Alnylam Pharmaceuticals by 15.8% during the 4th quarter. Capital International Investors now owns 3,586,657 shares of the biopharmaceutical company’s stock valued at $686,641,000 after purchasing an additional 488,814 shares during the period. Vanguard Group Inc. increased its position in Alnylam Pharmaceuticals by 2.5% during the 4th quarter. Vanguard Group Inc. now owns 11,943,895 shares of the biopharmaceutical company’s stock valued at $2,286,181,000 after purchasing an additional 287,064 shares during the period. Capital Research Global Investors increased its position in Alnylam Pharmaceuticals by 7.3% during the 1st quarter. Capital Research Global Investors now owns 3,144,987 shares of the biopharmaceutical company’s stock valued at $470,018,000 after purchasing an additional 214,908 shares during the period. Finally, Price T Rowe Associates Inc. MD increased its position in Alnylam Pharmaceuticals by 5.8% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,685,753 shares of the biopharmaceutical company’s stock valued at $550,837,000 after purchasing an additional 201,784 shares during the period. Institutional investors and hedge funds own 92.97% of the company’s stock.

Insider Activity at Alnylam Pharmaceuticals

In related news, CEO Yvonne Greenstreet sold 8,301 shares of the stock in a transaction on Tuesday, June 25th. The stock was sold at an average price of $230.99, for a total value of $1,917,447.99. Following the completion of the sale, the chief executive officer now directly owns 80,534 shares of the company’s stock, valued at approximately $18,602,548.66. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other news, Director Dennis A. Ausiello sold 20,250 shares of the firm’s stock in a transaction on Tuesday, August 6th. The stock was sold at an average price of $262.00, for a total transaction of $5,305,500.00. Following the completion of the sale, the director now directly owns 136 shares of the company’s stock, valued at approximately $35,632. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Yvonne Greenstreet sold 8,301 shares of the firm’s stock in a transaction on Tuesday, June 25th. The shares were sold at an average price of $230.99, for a total value of $1,917,447.99. Following the sale, the chief executive officer now directly owns 80,534 shares of the company’s stock, valued at $18,602,548.66. The disclosure for this sale can be found here. In the last three months, insiders sold 103,148 shares of company stock valued at $25,658,824. 1.50% of the stock is owned by insiders.

Analyst Ratings Changes

A number of analysts have weighed in on the stock. Leerink Partners increased their target price on shares of Alnylam Pharmaceuticals from $138.00 to $159.00 and gave the company a “market perform” rating in a research report on Tuesday, June 25th. TD Cowen increased their target price on shares of Alnylam Pharmaceuticals from $260.00 to $282.00 and gave the company a “buy” rating in a research report on Tuesday, June 25th. Stifel Nicolaus increased their price target on Alnylam Pharmaceuticals from $215.00 to $295.00 and gave the stock a “buy” rating in a report on Thursday, June 27th. Needham & Company LLC increased their price target on Alnylam Pharmaceuticals from $275.00 to $320.00 and gave the stock a “buy” rating in a report on Friday, August 2nd. Finally, JPMorgan Chase & Co. increased their price target on Alnylam Pharmaceuticals from $248.00 to $280.00 and gave the stock a “neutral” rating in a report on Monday, August 26th. Seven research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $279.14.

Alnylam Pharmaceuticals Trading Up 1.5 %

NASDAQ ALNY opened at $274.46 on Wednesday. The firm has a market capitalization of $34.72 billion, a P/E ratio of -102.41 and a beta of 0.38. The business has a fifty day simple moving average of $258.84 and a 200 day simple moving average of $195.93. Alnylam Pharmaceuticals, Inc. has a 12 month low of $141.98 and a 12 month high of $287.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.74) by $0.61. The company had revenue of $659.83 million during the quarter, compared to analysts’ expectations of $447.22 million. The company’s quarterly revenue was up 107.0% compared to the same quarter last year. During the same period in the previous year, the company posted ($2.21) earnings per share. As a group, sell-side analysts predict that Alnylam Pharmaceuticals, Inc. will post -2.73 EPS for the current fiscal year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.